ZHONGHENG GROUP(SH:600252) Shang Hai Zheng Quan Bao·2025-12-04 19:50Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Sichuan Yingrui Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, Nano Carbon Iron Suspension Injection, in combination with standard radiotherapy for solid tumor patients [1][2]. Group 1: Drug Information - The drug, named Nano Carbon Iron Suspension Injection, is developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd. and is classified as a Class 2 chemical drug [1]. - The drug targets solid tumors and utilizes Fe2+ as the active anti-cancer component, with nano carbon serving as its carrier, aiming to regulate ferroptosis pathways for anti-cancer effects [2]. - The clinical trial will explore the safety and potential efficacy of the combination therapy of Nano Carbon Iron and radiotherapy, particularly in challenging solid tumors [2]. Group 2: Research and Development - The cumulative R&D expenses for Nano Carbon Iron have reached approximately 94.28 million RMB (around 14.5 million USD) as of the announcement date [3]. - The second phase of clinical trials for Nano Carbon Iron is progressing smoothly, with some patient enrollment already completed [2]. - There are currently no similar products on the market or in late-stage research that directly target the ferroptosis pathway with exogenous Fe2+ [2].